Scientist with pills_Aptys_Pharma_Laboratory

We provide flexible solutions
adapted to industrial realism

What we do?

For over twenty years, Aptys pharma® has been actively involved in the galenic formulation and design of medicines.  This solid experience has led us to develop our own products for licensing or sale.

CEO_François_Boutignon_Aptys_Pharma

A unique and
determined vision

Discover our know-how

Aptys pharma® is a research and development company. We implement technologies to formulate or reformulate molecules. Our pharmaceutical and biotechnology expertise enables us to support our clients in the design and formulation, analytical development, and quality control of medicines.

An ongoing challenge
driven by passion

smart technology

Our ambition has always been to design and develop innovative medicines thanks to our proven know-how. Our galenic formulation patents are the synthesis of academic and industrial experience in the field of peptide-based medicines.

inventive

Aptys pharma® has developed many high-tech products under contract or for its own account, with the aim of selling the product once at an advanced stage of development.

Aptys_Pharma_

our
structure

Two laboratories

  • Formulation design laboratory
  • GMP compliant and a WHO-accredited analytical laboratory

Our
achievements

  • Preformulation analysis using SoluDiag® and NanoSolution® technology that are two fast and low raw material usage methods.
  • Formulation of immediate and controlled release tablets, microspheres, microcapsules, gels, creams, solutions, and suspensions.
  • Analytical development, validation, quality control and stability testing.

Latest news

bubbles

Metapain®

Metapain®: treatment of the first patients in the phase 3 clinical study in France.

Read more
bubbles

Aptys pharmaservices

The branch Aptys Pharmaservices successfully passed a regulatory inspection of Good Manufacturing Practices (GMP) by the French agency ANSM.

Read more
bubbles

Development Committee

Alain Eschalier, Michel Wurm, Michel Fradin and Thierry Legrier join the development committee.

Read more